EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Therapeutic outcomes of CAL/BDP PAD‑based cream in patients with mild-to-moderate psoriasis: insights from four case reports

Annunziata Dattola, Andrea Sechi, Luigi Gargiulo, Francesco Loconsole

Drugs in Context · 14.07.2026 · 1

DOI: 10.7573/dic.2026-5-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drugs in Context, online erschienen am 14.07.2026. Verfasst von Annunziata Dattola und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, Department of Medical and Cardiovascular Sciences, University of "La Sapienza", Rome, Italy. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Almirall S.p.A..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Topical medications are commonly used to manage mild‑to‑moderate psoriasis as adjunctive treatments in patients receiving phototherapy, systemic agents or biologic therapies. Amongst available topical options, the fixed-dose combination of calcipotriol (CAL) and betamethasone dipropionate (BDP) has demonstrated efficacy and tolerability in clinical trials, with most adverse events being mild and transient local reactions. CAL/ BDP has recently been formulated as a cream using polyaphron dispersion (PAD) technology to improve its rheological behaviour and sensory characteristics. We describe the use of CAL/BDP PAD‑based cream specifically in patients with mild‑to‑moderate psoriasis across four Italian centres. The first case involves a man with mild-to-moderate scalp psoriasis, in whom CAL/BDP PAD‑based cream was effective in this high‑impact disease location. The second case focuses on a patient with pretibial psoriasis, a difficult-to-treat site. The third case is of a woman with palmoplantar psoriasis who reported clinical improvement in the lesions and increased treatment compliance compared with her previous therapies. The last case describes the concomitant use of CAL/BDP PAD-based cream with a biologic drug, resulting in optimized lesion clearance. CAL/BDP PAD‑based cream appears promising for managing psoriasis in specific contexts such as lesions in difficult‑to‑treat areas or residual disease during biologic therapy. Further real‑world data and clinical observations will be important to clarify how this formulation can be integrated into individualized management strategies for mild-to-moderate psoriasis. Download the Plain Language Summary of this article: https://www.drugsincontext.com/plain-language-summaries/plain-language-summary-therapeutic-outcomes-of-cal-bdp-pad-based-cream-in-patients-with-mild-to-moderate-psoriasis-insights-from-four-case-reports

Schlagwörter

Stichwörter der Autor:innen

adherence, calcipotriolbetamethasone dipropionatechronic psoriasispalmoplantar psoriasispolyaphron dispersion technology

Autor:innen und Institutionen

  • Dermatology Unit, Department of Medical and Cardiovascular Sciences, University of "La Sapienza", Rome, Italy.
  • Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Dermatology Department, IRCCS Humanitas Research Hospital, Rozzano, Italy.
  • Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy.
  • Dermatology Department, Policlinico Universitario, Bari, Italy.

Förderung

  • Almirall S.p.A.

Zitieren

APA

Dattola, A., Sechi, A., Gargiulo, L., & Loconsole, F. (2026). Therapeutic outcomes of CAL/BDP PAD‑based cream in patients with mild-to-moderate psoriasis: insights from four case reports. Drugs in Context, 1. https://doi.org/10.7573/dic.2026-5-5

Vancouver

Dattola A, Sechi A, Gargiulo L, Loconsole F. Therapeutic outcomes of CAL/BDP PAD‑based cream in patients with mild-to-moderate psoriasis: insights from four case reports. Drugs in Context. 2026:1. doi:10.7573/dic.2026-5-5

BibTeX
@article{Dattola2026,
  author = {Dattola, Annunziata and Sechi, Andrea and Gargiulo, Luigi and Loconsole, Francesco},
  title = {Therapeutic outcomes of CAL/BDP PAD‑based cream in patients with mild-to-moderate psoriasis: insights from four case reports},
  journal = {Drugs in Context},
  year = {2026},
  pages = {1},
  doi = {10.7573/dic.2026-5-5}
}
Kostenlos starten →